Investor Relations

Listed On The Shanghai Stock Exchange In June 2001, With A Maximum Market Value Of 47.5 Billion

Ad hoc announcement pursuant to Art. 53 LR -JCARE Announcement on Re-appointment of Auditor

Time:2024-04-02

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on The Change of Supervisor and The Nomination of Candidate For Supervisor

Time:2024-04-02

Ad hoc announcement pursuant to Art. 53 LR -JCARE Announcement on the 2023 Profit Distribution Plan of the Company

Time:2024-04-02

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining the Approval Notice for Clinical Trial On Drug

Time:2024-02-22

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Drug Clinical Trial Approval for Semaglutide Injection

Time:2024-02-05

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Signing of Long-term Loan Agreement between the Company and International Finance Corporation

Time:2024-01-29

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2024 First Extraordinary General Meeting

Time:2024-01-18

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining Approval Notice for Clinical Trial

Time:2024-01-11

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Compound Ipratropium Bromide Solution for Inhalation Obtaining Drug Registration Approval in Philippine

Time:2024-01-09

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Provision for Impairment of Assets

Time:2024-01-09

< 1...91011...16 >